Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imatinib for Scleroderma Pulmonary Involvement
NCT00573326Phase 2Unknown
- Sponsor
- Azienda Ospedaliera Universitaria Policlinico
- Start
- Feb 2009
- Primary completion
- Jun 2010
- Countries
- 1
01
Overview
Phase 2, open-label trial of imatinib in systemic sclerosis (SSc), sponsored by Azienda Ospedaliera Universitaria Policlinico. Primary endpoint: Improvement of the pulmonary interstitial disease at 1 year. Status: unknown.
02
Drugs
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on NCT00573326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00573326.